SEC Filing Analysis: CORCEPT THERAPEUTICS INC (CORT)

Executive Summary

• Trading Significance: Low
• Key Takeaway: An officer executed a pre-planned sale of common stock valued at approximately $1.5 million following an option exercise, as part of a 10b5-1 trading plan.
• Market Impact: The transaction is considered routine and is unlikely to have a material impact on the stock due to its small size relative to the company's market capitalization and its pre-scheduled nature.

Company Information

Field	Value
Company	CORCEPT THERAPEUTICS INC
Ticker Symbol	CORT
CIK	0001088856
Industry	PHARMACEUTICAL PREPARATIONS [2834]

Insider Information

Field	Value
Name	Maduck Sean
CIK	0001698310
Title/Position	President, Corcept Endocrinology
Relationship	Officer

Transaction Details

This filing reports a 'sell-to-cover' transaction where stock options were exercised and the resulting shares were immediately sold.

Field	Value
Form Type	4
Transaction Date	2025-11-03
Transaction Code	S (Sale) / M (Option Exercise)
Security Type	Common Stock
Shares Involved	20,000 sold
Price Per Share	$73.9908 (Weighted Avg.)
Total Value	$1,479,816
Shares Owned After	117,621 (Direct & Indirect)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,479,816
% of Market Cap	0.019%
Shares Transacted	20,000
% of Shares Outstanding	0.019%
Post-Transaction Ownership	117,621 shares (0.11% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a market capitalization of $7.74 billion, this $1.5 million transaction is negligible and represents standard executive compensation activity rather than a strategic shift in ownership.
• Ownership Concentration: The insider's post-transaction ownership of 0.11% is not a controlling stake, and the sale of 20,000 shares does not significantly alter their position.
• Dilution Impact: The transaction involved the exercise of existing options, not the issuance of new ones. The sale itself has no dilutive impact.
• Transaction Significance: The sale represents approximately 14.5% of the insider's total holdings. While a notable portion of their personal stake, the small size relative to the company's public float and the pre-planned nature under a 10b5-1 plan mitigate its significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale was conducted under a pre-disclosed 10b5-1 trading plan, which removes the element of discretionary timing. Such sales are typically for personal financial planning, diversification, or tax purposes and are not interpreted as a change in the insider's outlook on the company.

Volume & Sentiment

• Expected Volume Impact: Minimal. The transaction size is too small to significantly affect trading volume.
• Sentiment Indicator: Neutral. The market generally views pre-planned 10b5-1 sales as non-events.

Additional Context

Transaction Notes

• Special Circumstances: The filing explicitly notes the sale was made pursuant to a 10b5-1 plan adopted on September 5, 2024. The transaction involved exercising options at $8.27 per share and subsequently selling the acquired 20,000 shares at an average price of $73.9908.